Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Profiling Plasmodium falciparum parasites and human red blood cells after treatment with MMV693183

ABSTRACT: Compound MMV693183 was added to either Plasmodium falciparum or uninfected red blood cells. The concentrations used were 240 nM, 24 nM, and 2.4 nM. Untreated parasites and red blood cells were also used as controls.

ORGANISM(S): Human Homo Sapiens Plasmodium Falciparum

TISSUE(S): Cultured Cells, Blood

DISEASE(S): Malaria

SUBMITTER: Manuel Llinás

PROVIDER: ST001985 | MetabolomicsWorkbench | Tue Oct 26 00:00:00 BST 2021

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

CD1c+ dendritic cell activation by Plasmodium falciparum-infected red blood cells

Project description:CD1c+ dendritic cell activation by Plasmodium falciparum-infected red blood cells

2017-11-11 | GSE89087 | GEO

RNA-seq of human peripheral blood mononuclear cells exposed to red blood cells infected with Plasmodium falciparum

Project description:Peripheral Blood Mononuclear Cells were isolated from three individuals. Cells from these biological replicates were exposed to Red Blood Cells (male donor age 27) infected with Plasmodium falciparum, uninfected Red Blood Cells, or RPMI prior to stimulation with PAM3CSK4 (10g/mL) for 0, 4, and 12 hours. Total RNA was extracted using the Aurum Total RNA Mini Kit (BioRad). Samples were eluted in nuclease-free water and analyzed for concentration and fragment analysis using an Agilent Fragment Analyzer (Agilent). For each sample, 0.5 g of total RNA was used to prepare RNA-seq libraries using the TruSeq Stranded Total RNA Library Prep Human/Mouse/Rat kit and the TruSeq RNA single indexes Set A (Illumina) according to the manufacturer’s instructions. Samples were sequenced at the Bauer Sequencing Core at Harvard University on a HiSeq 2500 (Illumina), using paired-end 75bp sequencing.

2020-05-15 | E-MTAB-9066 | biostudies-arrayexpress

Global gene expression of the rodent malaria parasites Plasmodium yoelii, Plasmodium berghei and Plasmodium chabaudi blood-stage parasites

Project description:The purpose of this research is to identify and evaluate the global gene expression of the rodent malaria parasites Plasmodium yoelii, Plasmodium berghei and Plasmodium chabaudi blood-stage parasites and specifically compare the blood stage gene expression profiles of samples derived from previous studies on Plasmodium falciparum, Plasmodium vivax and Plasmodium knowlesi

2016-04-08 | GSE80015 | GEO

Plasmodium falciparum blood stage parasites: control vs PfTRF-depleted parasites

Project description:Transcriptional profiling of transgenic Plasmodium falciparum blood stage parasites expressing the telomere repeat-binding factor PfTRF as a C-terminal GFP-DD fusion (3D7/TRFGFP-ON). The DD (FKBP destabilisation domain) allows for the conditional depletion of fusion proteins in absence of the stabilising ligand Shield-1 (Banaszynski LA, Chen LC, Maynard-Smith LA, Ooi AG, Wandless TJ. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules.Cell. 2006 Sep 8;126(5):995-1004). The goal of this experiment was to identify genes differentially expressed in response to PfTRF depletion.

2016-07-14 | GSE84342 | GEO

Red blood cell BCL-xL is required for Plasmodium falciparum survival: insights into host-directed malaria therapies

Project description:The development of antimalarial drug resistance is an ongoing problem threatening progress towards malaria elimination, and antimalarial treatments are urgently needed for drug-resistant malaria infections. Host-directed therapies (HDT) represent an attractive strategy for the devel-opment of new antimalarials with untapped targets and low propensity for resistance. In addi-tion, drug repurposing in the context of HDT can lead to a substantial decrease in the time and resources required to develop novel antimalarials. Host BCL-XL is a major target in anti-cancer therapy and is essential for the development of numerous intracellular pathogens. We hypothe-sised that red blood cell BCL-XL is essential for Plasmodium development and tested this hypoth-esis by using six BCL-XL inhibitors, including one FDA-approved compound. All BCL-xL inhibitors tested impaired proliferation of P. falciparum 3D7 parasites in vitro at low parasite inhibitory concentrations. Western blot analysis and immunofluorescence microscopy assays revealed that host BCL-xL is transferred from the host red blood cells (RBCs) to the parasite upon infection. Further, immunoprecipitation of BCL-XL coupled with mass spectrometry analysis identified that BCL-XL forms unique molecular complexes with human μ-calpain in uninfected RBCs, and with human SHOC2 in infected RBCs. These results open exciting perspectives for the development of host-directed antimalarial therapies and drug repurposing efforts.

2022-05-19 | PXD032276 | Pride

Transcriptional analysis of the early liver stage of Plasmodium falciparum parasites

Project description:Determination of gene expression level changes of whole genome during Plasmodium falciparum development in early liver stage (at 24h and 48h), compared to mixed blood stage and sporozoite stage. A set of Genes selected from this expression analysis are further verified by qPCR and a sub-set were tested for their vaccine efficacy. 6 genomic tiling arrays: 3 time points in early liver infection (spz, hr24, hr48), and 3 blood stage isolates

2014-07-01 | E-GEOD-56959 | biostudies-arrayexpress

Transcription profiling of human endothelial cells treated with Plasmodium falciparum-infected erythrocytes and/or TNF-alpha

Project description:Sensitisation of endothelium to TNFalpha induced by cytoadherence of Plasmodium falciparum infected red blood cells

2007-06-05 | E-SGRP-3 | biostudies-arrayexpress

Peroxide antimalarial treatment timecourse on trophozoite-stage P. falciparum parasites

Project description:Red blood cells (RBCs) infected with trophozoite stage P. falciparum parasites (3D7 strain) at 10% parasitaemia and 2% haematocrit were treated with OZ277 (300 nM), OZ439 (300 nM), DHA (100 nM) or vehicle (0.03% DMSO). This was a 4-timepoint study, with samples taken 0, 0.5, 1.5 and 3 h after drug or vehicle addition. Samples treated with vehicle acted as the untreated control. Samples from drug treated uninfected RBCs were also taken to ensure the observed drug effects were parasite specific.

2019-06-19 | ST001201 | MetabolomicsWorkbench

Peroxide antimalarial drugs impact redox homeostasis in Plasmodium falciparum infected red blood cells

Project description:Plasmodium falciparum causes the most lethal form of malaria. The frontline treatments for this severe disease are combination therapies based on semisynthetic peroxide antimalarials, known as artemisinins. There is growing resistance to artemisinins and new drugs with novel mechanisms of action are urgently required. Synthetic peroxide antimalarials, known as ozonides, exhibit potent antimalarial activity both in vitro and in vivo. Here, we used chemical proteomics to investigate the protein alkylation targets of clickable artemisinin and ozonide probes, including an analogue of the ozonide clinical candidate, OZ439. We greatly expanded the list of protein targets for peroxide antimalarials and identified redox processes as being significantly enriched from the list of protein targets for both artemisinins and ozonides. Disrupted redox homeostasis was confirmed with the use of a genetically encoded fluorescence-based biosensor comprising a redox-sensitive GFP (roGFP) fused to human glutaredoxin 1. This facilitated specific and dynamic live imaging of the glutathione redox potential in the cytosol of peroxide-treated infected red blood cells with high sensitivity and temporal resolution. We also used a targeted LC-MS based thiol metabolomics assay to accurately measure relative changes in cellular thiol levels (including thiol metabolites, glutathione precursors and oxidised and reduced glutathione) within peroxide-treated P. falciparum-infected red blood cells. This work shows that peroxide antimalarials disproportionately alkylate proteins involved in redox homeostasis and that disrupted redox processes are involved in the mechanism of action of these important antimalarials.

2022-02-17 | PXD027334 | Pride

Peroxide antimalarial extended treatment timecourse on trophozoite-stage P. falciparum parasites

Project description:Red blood cells (RBCs) infected with trophozoite stage P. falciparum parasites (3D7 strain) at 10% parasitaemia and 2% haematocrit were treated with OZ277 (300 nM), OZ439 (300 nM), DHA (100 nM) or vehicle (0.03% DMSO). This was a 4-timepoint study, with samples taken 0, 3, 6 and 9 h after drug or vehicle addition. Samples treated with vehicle acted as the untreated control. Samples from drug treated uninfected RBCs were also taken to ensure the observed drug effects were parasite specific.

2019-06-25 | ST001204 | MetabolomicsWorkbench

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data